Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.

Adult Aged Aged, 80 and over Antineoplastic Agents, Hormonal / therapeutic use Breast Neoplasms / drug therapy Carcinoma, Ductal, Breast / drug therapy Carcinoma, Lobular / drug therapy Female Follow-Up Studies Fulvestrant / therapeutic use Humans Middle Aged Neoplasm Recurrence, Local / drug therapy Postmenopause Prognosis Receptor, ErbB-2 / metabolism Receptors, Estrogen / metabolism Receptors, Progesterone / metabolism Retrospective Studies Survival Rate
Antineoplastic agents Breast cancer Hormones Overall survival Post-menopause

Journal

Breast cancer (Tokyo, Japan)
ISSN: 1880-4233
Titre abrégé: Breast Cancer
Pays: Japan
ID NLM: 100888201

Informations de publication

Date de publication:
May 2020
Historique:
received: 24 06 2019
accepted: 28 11 2019
pubmed: 8 12 2019
medline: 3 2 2021
entrez: 8 12 2019
Statut: ppublish

Résumé

Assessing survival risk is important for discussing treatment options with estrogen receptor-positive (ER+) advanced breast cancer (ABC) patients. However, there are few reports from large-scale databases on the survival risk factors in ER+ ABC. The Safari study (UMIN000015168) was a retrospective, multicenter cohort study involving 1072 Japanese patients receiving fulvestrant 500 mg mostly as a second- or later-line endocrine therapy for ER+ ABC. The follow-up data after the Safari study were examined, focusing on any relationship between clinicopathological factors and overall survival (OS) in ER+ ABC patients. OS in patients with ER+ ABC was analyzed by univariate and multivariate analyses with a Cox proportional hazards model in this study. A total of 1031 cases were evaluable for OS analysis. Multivariate analysis showed that younger age (< 60 years), longer time from ABC diagnosis to fulvestrant use (≥ 3 years), no prior palliative chemotherapy before fulvestrant use, and progesterone receptor (PgR) negativity (PgR-) were significantly correlated with prolonged OS (median 7.0 years). For cases with histological or nuclear grade data, lower histological or nuclear grades were also correlated with longer OS. In recurrent metastatic cases, long disease-free interval (DFI) was not correlated with longer OS. In ER+ ABC patients whose treatment history included fulvestrant, younger age, longer time from ABC diagnosis to fulvestrant use, no prior palliative chemotherapy use, PgR-, and lower histological or nuclear grade correlated positively with prolonged OS.

Sections du résumé

BACKGROUND BACKGROUND
Assessing survival risk is important for discussing treatment options with estrogen receptor-positive (ER+) advanced breast cancer (ABC) patients. However, there are few reports from large-scale databases on the survival risk factors in ER+ ABC. The Safari study (UMIN000015168) was a retrospective, multicenter cohort study involving 1072 Japanese patients receiving fulvestrant 500 mg mostly as a second- or later-line endocrine therapy for ER+ ABC. The follow-up data after the Safari study were examined, focusing on any relationship between clinicopathological factors and overall survival (OS) in ER+ ABC patients.
METHODS METHODS
OS in patients with ER+ ABC was analyzed by univariate and multivariate analyses with a Cox proportional hazards model in this study.
RESULTS RESULTS
A total of 1031 cases were evaluable for OS analysis. Multivariate analysis showed that younger age (< 60 years), longer time from ABC diagnosis to fulvestrant use (≥ 3 years), no prior palliative chemotherapy before fulvestrant use, and progesterone receptor (PgR) negativity (PgR-) were significantly correlated with prolonged OS (median 7.0 years). For cases with histological or nuclear grade data, lower histological or nuclear grades were also correlated with longer OS. In recurrent metastatic cases, long disease-free interval (DFI) was not correlated with longer OS.
CONCLUSIONS CONCLUSIONS
In ER+ ABC patients whose treatment history included fulvestrant, younger age, longer time from ABC diagnosis to fulvestrant use, no prior palliative chemotherapy use, PgR-, and lower histological or nuclear grade correlated positively with prolonged OS.

Identifiants

DOI: 10.1007/s12282-019-01029-3 PMID: 31811519 PMC: PMC7196081
pubmed: 31811519
doi: 10.1007/s12282-019-01029-3
pii: 10.1007/s12282-019-01029-3
pmc: PMC7196081
doi:

Substances chimiques

Antineoplastic Agents, Hormonal 0
Receptors, Estrogen 0
Receptors, Progesterone 0
Fulvestrant 22X328QOC4
ERBB2 protein, human EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

389-398

Références

EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127–35. https://doi.org/10.1016/S0140-6736(14)60488-8 .
doi: 10.1016/S0140-6736(14)60488-8
Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis. J Intern Med. 2013;274:113–26. https://doi.org/10.1111/joim.12084 .
doi: 10.1111/joim.12084 pubmed: 23844915 pmcid: 3711134
Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23:vii11-9. https://doi.org/10.1093/annonc/mds232 .
doi: 10.1093/annonc/mds232 pubmed: 22997442
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, et al. 3rd ESO–ESMO International consensus guidelines for Advanced Breast Cancer (ABC 3). Breast. 2017;31:244–59. https://doi.org/10.1016/j.breast.2016.10.001 .
doi: 10.1016/j.breast.2016.10.001 pubmed: 27927580
Migliaccio I, Malorni L, Hart CD, Guarducci C, Di Leo A. Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers. BMC Med. 2015;13:46. https://doi.org/10.1186/s12916-015-0280-0 .
doi: 10.1186/s12916-015-0280-0 pubmed: 25857348 pmcid: 4350905
Başaran GA, Twelves C, Diéras V, Cortés J, Awada A. Ongoing unmet needs in treating estrogen receptor positive/HER2-negative metastatic breast cancer. Cancer Treat Rev. 2018;63:144–55. https://doi.org/10.1016/j.ctrv.2017.12.002 .
doi: 10.1016/j.ctrv.2017.12.002 pubmed: 29329006
Brodowicz T, Lang I, Kahan Z, Greil R, Beslija S, Stemmer SM, et al. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. Br J Cancer. 2014;111:2051–7. https://doi.org/10.1038/bjc.2014.504 .
doi: 10.1038/bjc.2014.504 pubmed: 25268370 pmcid: 4260030
Zhang XH, Giuliano M, Trivedi MV, Schiff R, Osborne CK. Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 2013;19:6389–97. https://doi.org/10.1158/1078-0432.CCR-13-0838 .
doi: 10.1158/1078-0432.CCR-13-0838 pubmed: 24298069
Ignatiadis M, Sotiriou C. Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol. 2013;10:494–506. https://doi.org/10.1038/nrclinonc.2013.124 .
doi: 10.1038/nrclinonc.2013.124 pubmed: 23881035
Llombart-Cussac A, Pivot X, Biganzoli L, Cortes-Funes H, Pritchard KI, Pierga JY, et al. A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial. Breast. 2014;23:656–62. https://doi.org/10.1016/j.breast.2014.06.017 .
doi: 10.1016/j.breast.2014.06.017 pubmed: 25047747
Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003;21:588–92. https://doi.org/10.1200/JCO.2003.08.013 .
doi: 10.1200/JCO.2003.08.013 pubmed: 12586793
Yamamoto N, Watanabe T, Katsumata N, Omuro Y, Ando M, Fukuda H, et al. Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol. 1998;16:2401–8. https://doi.org/10.1200/JCO.1998.16.7.2401 .
doi: 10.1200/JCO.1998.16.7.2401 pubmed: 9667257
Yamamura J, Kamigaki S, Tsujie M, Fujita J, Osato H, Higashi C, et al. Response to first-line recurrence treatment influences survival in hormone receptor-positive, HER2-negative breast cancer: a multicenter study. Vivo. 2019;33:281–7. https://doi.org/10.21873/invivo.11473 .
doi: 10.21873/invivo.11473
Ogiya A, Yamazaki K, Horii R, Shien T, Horimoto Y, Masuda N, et al. Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor positive HER2-negative breast cancer. Breast Cancer 2017;24:473–82. https://hdl.handle.net/2115/70047
Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, et al. Outcomes of fulvestrant therapy among Japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari). Breast Cancer Res Treat. 2017;163:545–54. https://doi.org/10.1007/s10549-017-4212-x .
doi: 10.1007/s10549-017-4212-x pubmed: 28337663
Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, et al. Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study. Curr Med Res Opin. 2018;34:49–544. https://doi.org/10.1080/03007995.2017.1400426 .
doi: 10.1080/03007995.2017.1400426 pubmed: 29095648
Faslodex
Faslodex
Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E, ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii11-9.
pubmed: 22997442
National Comprehensive Cancer Network. Invasive breast cancer (Version 4.2018). Fort Washington (PA): NCCN; 2017. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp . Accessed 5 May 2019
Caswell-Jin JL, Plevritis SK, Tian L, Cadham CJ, Xu C, Stout NK, et al. Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review. JNCI Cancer Spectr. 2018;2:pky062. https://doi.org/10.1093/jncics/pky062 .
doi: 10.1093/jncics/pky062 pubmed: 30627694 pmcid: 6305243
Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, et al. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? Br J Cancer. 2015;112:1445–511. https://doi.org/10.1038/bjc.2015.127 .
doi: 10.1038/bjc.2015.127 pubmed: 25880008 pmcid: 4453676
Chen MT, Sun HF, Zhao Y, Fu WY, Yang LP, Gao SP, et al. Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis. Sci Rep. 2017;23(7):9254. https://doi.org/10.1038/s41598-017-10166-8 .
doi: 10.1038/s41598-017-10166-8
Hojo T, Masuda N, Mizutani T, Shibata T, Kinoshita T, Tamura K, et al. Intensive vs. standard post-operative surveillance in high-risk breast cancer patients (INSPIRE): Japan Clinical Oncology Group Study JCOG1204. Jpn J Clin Oncol. 2015;45:983–6. https://doi.org/10.1093/jjco/hyv110 .
doi: 10.1093/jjco/hyv110 pubmed: 26246481
Gordis L. Epidemiology. Philadelphia: Saunders; 2008. p. 318.
Abe S. Japan’s vision for a peaceful and healthier world. Lancet. 2015;386:2367–9. https://doi.org/10.1016/S0140-6736(15)01172-1 .
doi: 10.1016/S0140-6736(15)01172-1 pubmed: 26700515 pmcid: 7138109
Abe S. Japan's strategy for global health diplomacy: why it matters. Lancet. 2013;382:915–6. https://doi.org/10.1016/S0140-6736(13)61639-6 .
doi: 10.1016/S0140-6736(13)61639-6 pubmed: 24034284
Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, et al. Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol. 2008;19:2012–9. https://doi.org/10.1093/annonc/mdn424 .
doi: 10.1093/annonc/mdn424 pubmed: 18641006 pmcid: 2733115
Sánchez C, Camus M, Medina L, Oddo D, Artigas RC, Pérez Sepúlveda A, et al. Clinico-pathologic subtypes of breast cancer primary tumors are related to prognosis after recurrence. Asian Pac J Cancer Prev. 2016;17:5081–6.
pubmed: 28122438 pmcid: 5454640
Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol. 2018;29:1634–57. https://doi.org/10.1093/annonc/mdy192 .
doi: 10.1093/annonc/mdy192 pubmed: 30032243
Huang X, Cormier JN, Pisters PW. Estimation of the causal effects on survival of two-stage nonrandomized treatment sequences for recurrent diseases. Biometrics. 2006;62:901–9.
doi: 10.1111/j.1541-0420.2005.00520.x

Auteurs

Hidetoshi Kawaguchi (H)

Department of Breast Surgery, Matsuyama Red Cross Hospital, 1 Bunkyo-cho, Matsuyama, 790-8524, Japan. hkawaguchi@matsuyama.jrc.or.jp.
ORCID: 0000-0002-0811-9335

Norikazu Masuda (N)

Department of Surgery, Breast Oncology, NHO Osaka National Hospital, Osaka, 540-0006, Japan.

Takahiro Nakayama (T)

Department of Breast and Endocrine Surgery, Osaka International Cancer Institute, Osaka, 541-8567, Japan.

Kenjiro Aogi (K)

Department of Breast Oncology, NHO Shikoku Cancer Center, Matsuyama, 791-0280, Japan.

Keisei Anan (K)

Department of Surgery, Kitakyushu Municipal Medical Center, Kitakyushu, 802-0077, Japan.

Yoshinori Ito (Y)

Department of Breast Medical Oncology, The Cancer Institute Hospital of JFCR, Tokyo, 135-8550, Japan.

Shoichiro Ohtani (S)

Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, 730-8518, Japan.

Nobuaki Sato (N)

Department of Breast Oncology, Niigata Cancer Center Hospital, Niigata, 951-8566, Japan.

Shigehira Saji (S)

Department of Medical Oncology, Fukushima Medical University, Fukushima, 960-1295, Japan.

Toshimi Takano (T)

Department of Medical Oncology, Toranomon Hospital, Tokyo, 105-8470, Japan.

Eriko Tokunaga (E)

Department of Breast Oncology, Kyushu Cancer Center, Fukuoka, 811-1395, Japan.

Seigo Nakamura (S)

Department of Surgery, Division of Breast Surgical Oncology, Showa University School of Medicine, Tokyo, 142-8666, Japan.

Yoshie Hasegawa (Y)

Department of Breast Surgery, Hirosaki Municipal Hospital, Hirosaki, 036-8004, Japan.

Masaya Hattori (M)

Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, 464-8681, Japan.

Tomomi Fujisawa (T)

Department of Breast Oncology, Gunma Prefectural Cancer Center, Ohta, 373-8550, Japan.

Satoshi Morita (S)

Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan.

Miki Yamaguchi (M)

Department of Breast Surgery, JCHO Kurume General Hospital, Kurume, 830-0013, Japan.

Hiroko Yamashita (H)

Department of Breast Surgery, Hokkaido University Hospital, Sapporo, 060-8648, Japan.

Toshinari Yamashita (T)

Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, 241-8515, Japan.

Yutaka Yamamoto (Y)

Department of Breast and Endocrine Surgery, Kumamoto University Graduate School of Medical Sciences, Kumamoto, 860-8556, Japan.

Daisuke Yotsumoto (D)

Department of Breast Surgical Oncology, Hakuaikai Medical Corporation Sagara Hospital, Kagoshima, 892-0833, Japan.

Masakazu Toi (M)

Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan.

Shinji Ohno (S)

Breast Oncology Center, The Cancer Institute Hospital of JFCR, Tokyo, 135-8550, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Factors associated with prolonged overall...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Factors associated with prolonged overall...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Factors associated with prolonged overall...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques hormonaux › Factors associated with prolonged overall...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Factors associated with prolonged overall...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Carcinome canalaire du sein › Factors associated with prolonged overall...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Carcinome lobulaire › Factors associated with prolonged overall...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études de suivi › Factors associated with prolonged overall...
questionsmedicales.fr › Hormones gonadiques › Hormones sexuelles stéroïdiennes › Congénères de l'oestradiol › Oestradiol › Fulvestrant › Factors associated with prolonged overall...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Factors associated with prolonged overall...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Factors associated with prolonged overall...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Factors associated with prolonged overall...
questionsmedicales.fr › Phénomènes physiologiques des appareils urinaire et reproducteur › Phénomènes physiologiques de la reproduction › Développement sexuel › Climatère › Ménopause › Post-ménopause › Factors associated with prolonged overall...
questionsmedicales.fr › Diagnostic › Pronostic › Factors associated with prolonged overall...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Récepteur ErbB-2 › Factors associated with prolonged overall...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Récepteurs aux stéroïdes › Récepteurs des oestrogènes › Factors associated with prolonged overall...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Récepteurs cytoplasmiques et nucléaires › Récepteurs à la progestérone › Factors associated with prolonged overall...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Factors associated with prolonged overall...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Mortalité › Taux de survie › Factors associated with prolonged overall...